Prognostic and Risk Factors in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma of the Trunk and Extremities

Overview

Journal J Skin Cancer

Publisher Wiley

Specialty Dermatology

Date 2011 Jul 21

PMID 21773035

Citations 11

Authors

de Lima Vazquez Vinicius

Cristovam Scapulatempo

Natalia Martins Perpetuo

Faheez Mohamed

Teoclito Sachetto de Carvalho

Antonio Talvane Torres de Oliveira

Jose Getulio Martins Segalla

Andre Lopes Carvalho

Affiliations

Soon will be listed here.

Abstract

55 patients with advanced cutaneous squamous cell carcinoma (CSCC) of the trunk and extremities were studied. A Tissue Microarray was constructed using immunohistochemistry to quantify expression of the HER family, E-cadherins, and podoplanin. Clinical and histopathological factors related to lymph node metastasis and prognosis were also established. Primary tumor positivity was 25.5% for EGFR, 87.3% for HER-3, and 48.1% for HER-4. Metastases were positive for EGFR in 41.7%, for HER-3 in 83.3%, and HER-4 in 43.5%. HER-2 was negative in all samples. Membrane E-cadherin and cytoplasmic E-cadherin were positive in 47.3% and 30.2% of primary tumors and 45.5% and 27.3% of metastases, respectively. Podoplanin was positive in 41.8% of primary tumors and 41.7% of metastases. Intratumoral lymphocytic infiltrate was associated with lymph node metastasis. Patients with T3 tumors had better cancer-specific survival (CSS) than those with T4 tumors; patients with no lymph node involvement had better CSS than patients with N1 tumors. Undifferentiated tumors and hyperexpression of podoplanin were negative prognostic indicators on multivariate analysis.

Citing Articles

Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line.

Laus A, Gomes I, da Silva A, Sussuchi da Silva L, Milan M, AparecidaTeixeira S Hum Cell. 2024; 37(4):1170-1183.

PMID: 38565739 PMC: 11194207. DOI: 10.1007/s13577-024-01054-1.

Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous-cell carcinomas (Review).

Balasescu E, Gheorghe A, Moroianu A, Turcu G, Brinzea A, Antohe M Exp Ther Med. 2022; 23(6):383.

PMID: 35495612 PMC: 9019737. DOI: 10.3892/etm.2022.11308.

E-cadherin, fibronectin and Slug immunoexpression in non-melanoma skin cancers.

Ciuciulete A, Stepan A, Badiu A, Andreiana B, Florescu M, Simionescu C Rom J Morphol Embryol. 2022; 62(3):705-712.

PMID: 35263398 PMC: 9019669. DOI: 10.47162/RJME.62.3.07.

The Role of Podoplanin in Skin Diseases.

Asai J Int J Mol Sci. 2022; 23(3).

PMID: 35163233 PMC: 8836045. DOI: 10.3390/ijms23031310.

Roles of Podoplanin in Malignant Progression of Tumor.

Suzuki H, Kaneko M, Kato Y Cells. 2022; 11(3).

PMID: 35159384 PMC: 8834262. DOI: 10.3390/cells11030575.

References

de Lima Vazquez V, Sachetto T, Perpetuo N, Carvalho A . Prognostic factors for lymph node metastasis from advanced squamous cell carcinoma of the skin of the trunk and extremities. World J Surg Oncol. 2008; 6:73. PMC: 2467422. DOI: 10.1186/1477-7819-6-73. View

Joseph M, Zulueta W, Kennedy P . Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome. Aust N Z J Surg. 1992; 62(9):697-701. DOI: 10.1111/j.1445-2197.1992.tb07065.x. View

North Jr J, Spellman J, Driscoll D, Velez A, Kraybill W, Petrelli N . Advanced cutaneous squamous cell carcinoma of the trunk and extremity: analysis of prognostic factors. J Surg Oncol. 1997; 64(3):212-7. DOI: 10.1002/(sici)1096-9098(199703)64:3<212::aid-jso7>3.0.co;2-d. View

Ames F, HICKEY R . Metastasis from squamous cell skin cancer of the extremities. South Med J. 1982; 75(8):920-3, 932. DOI: 10.1097/00007611-198208000-00005. View

Krahn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G . Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer. 2001; 37(2):251-9. DOI: 10.1016/s0959-8049(00)00364-6. View

Fogarty G, Conus N, Chu J, McArthur G . Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol. 2007; 156(1):92-8. DOI: 10.1111/j.1365-2133.2006.07603.x. View

Rosenblatt L, Marks R . Deaths due to squamous cell carcinoma in Australia: is there a case for a public health intervention?. Australas J Dermatol. 1996; 37(1):26-9. DOI: 10.1111/j.1440-0960.1996.tb00990.x. View

Mettlin C . Skin cancer and ozone depletion: the case for global action. J Surg Oncol. 2001; 77(2):76-8. DOI: 10.1002/jso.1072. View

Nollet F, Berx G, VAN Roy F . The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun. 1999; 2(2):77-85. DOI: 10.1006/mcbr.1999.0155. View

10.

Ahmed N, Ueda M, Ichihashi M . Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma. Br J Dermatol. 1997; 136(6):908-12. View

11.

Yang H, Cabral E, Dadras S, Cassarino D . Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am J Dermatopathol. 2008; 30(6):549-54. DOI: 10.1097/DAD.0b013e31816d6513. View

12.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

13.

Nawrocki B, Polette M, van Hengel J, Tournier J, VAN Roy F, Birembault P . Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with down-regulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am J Pathol. 1998; 153(5):1521-30. PMC: 1853397. DOI: 10.1016/s0002-9440(10)65740-9. View

14.

Schacht V, Ramirez M, Hong Y, Hirakawa S, Feng D, Harvey N . T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003; 22(14):3546-56. PMC: 165612. DOI: 10.1093/emboj/cdg342. View

15.

Czarnecki D, Staples M, Mar A, Giles G, Meehan C . Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatology. 1994; 189(1):52-4. DOI: 10.1159/000246783. View

16.

Ordonez N . D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol. 2005; 36(4):372-80. DOI: 10.1016/j.humpath.2005.01.019. View

17.

Cherpelis B, Marcusen C, Lang P . Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg. 2002; 28(3):268-73. DOI: 10.1046/j.1524-4725.2002.01169.x. View

18.

Padgett D, Cathro H, Wick M, Mills S . Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 2007; 32(1):123-7. DOI: 10.1097/PAS.0b013e31814faacf. View

19.

Moore B, Weber R, Prieto V, El-Naggar A, Holsinger F, Zhou X . Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005; 115(9):1561-7. DOI: 10.1097/01.mlg.0000173202.56739.9f. View

20.

Maubec E, Duvillard P, Velasco V, Crickx B, Avril M . Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res. 2005; 25(2B):1205-10. View